Potential relation of cardiovascular risk factors to disease activity in patients with axial spondyloarthritis.
axial spondyloarthritis
cardiovascular risk factors
disease activity
Journal
Therapeutic advances in musculoskeletal disease
ISSN: 1759-720X
Titre abrégé: Ther Adv Musculoskelet Dis
Pays: England
ID NLM: 101517322
Informations de publication
Date de publication:
2021
2021
Historique:
received:
17
02
2021
accepted:
18
05
2021
entrez:
11
8
2021
pubmed:
12
8
2021
medline:
12
8
2021
Statut:
epublish
Résumé
Axial spondyloarthritis (axSpA) patients are known to have a higher prevalence of several comorbidities, including, among others, an increased risk of atherosclerosis, hypertension, dyslipidemia, and diabetes. The purpose of the present study was to determine whether the sum of traditional cardiovascular (CV) risk factors is related to disease characteristics, such as disease activity, in patients with axSpA. A cross-sectional study that encompassed 804 patients with axSpA was conducted. Patients were assessed for the presence of five traditional CV risk factors (diabetes mellitus, dyslipidemia, hypertension, obesity, and smoking status), and disease activity measurements. A multivariable regression analysis was performed to evaluate whether the number of classic CV risk factors was independently associated with specific features of the disease, to include disease activity. A multivariable analysis showed that Ankylosing Spondylitis Disease Activity Score-C reactive protein (ASDAS-CRP) activity score was significantly higher in patients with 1 [beta coefficient 0.3 (95% confidence interval (CI) 0.1-0.5), Among patients with axSpA, as the number of traditional CV risk factors increased, disease activity similarly increases in an independent manner.
Sections du résumé
BACKGROUND
BACKGROUND
Axial spondyloarthritis (axSpA) patients are known to have a higher prevalence of several comorbidities, including, among others, an increased risk of atherosclerosis, hypertension, dyslipidemia, and diabetes. The purpose of the present study was to determine whether the sum of traditional cardiovascular (CV) risk factors is related to disease characteristics, such as disease activity, in patients with axSpA.
METHODS
METHODS
A cross-sectional study that encompassed 804 patients with axSpA was conducted. Patients were assessed for the presence of five traditional CV risk factors (diabetes mellitus, dyslipidemia, hypertension, obesity, and smoking status), and disease activity measurements. A multivariable regression analysis was performed to evaluate whether the number of classic CV risk factors was independently associated with specific features of the disease, to include disease activity.
RESULTS
RESULTS
A multivariable analysis showed that Ankylosing Spondylitis Disease Activity Score-C reactive protein (ASDAS-CRP) activity score was significantly higher in patients with 1 [beta coefficient 0.3 (95% confidence interval (CI) 0.1-0.5),
CONCLUSION
CONCLUSIONS
Among patients with axSpA, as the number of traditional CV risk factors increased, disease activity similarly increases in an independent manner.
Identifiants
pubmed: 34377161
doi: 10.1177/1759720X211033755
pii: 10.1177_1759720X211033755
pmc: PMC8323406
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1759720X211033755Informations de copyright
© The Author(s), 2021.
Déclaration de conflit d'intérêts
Conflict of interest statement: MAG-G and IF-A would like to acknowledge that they received grants/research supports from Abbott, MSD, Jansen, and Roche, as well as consultation fees from company-sponsored speakers bureaus associated with Abbott, Pfizer, Roche, Sanofi, Celgene, and MSD.
Références
J Rheumatol. 1994 Dec;21(12):2286-91
pubmed: 7699630
Arterioscler Thromb Vasc Biol. 2002 Oct 1;22(10):1668-73
pubmed: 12377747
J Rheumatol. 2019 Jul;46(7):701-709
pubmed: 30647169
Ann Rheum Dis. 2009 Jan;68(1):18-24
pubmed: 18625618
Rheumatology (Oxford). 2020 Oct 1;59(Suppl4):iv47-iv57
pubmed: 33053193
J Rheumatol. 1994 Dec;21(12):2281-5
pubmed: 7699629
Nat Med. 2011 Feb;17(2):179-88
pubmed: 21217695
Mediators Inflamm. 2013;2013:710928
pubmed: 23431244
J Am Coll Cardiol. 2005 Dec 6;46(11):1978-85
pubmed: 16325028
Medicina (Kaunas). 2020 Aug 18;56(8):
pubmed: 32824666
JAMA. 2011 Jun 22;305(24):2525-31
pubmed: 21693740
J Rheumatol. 1994 Sep;21(9):1694-8
pubmed: 7799351
Ann Rheum Dis. 2017 Jan;76(1):17-28
pubmed: 27697765
Circulation. 2003 Dec 16;108(24):2957-63
pubmed: 14676136
Clin Exp Rheumatol. 2013 Jul-Aug;31(4):612-20
pubmed: 23406817
Ann Rheum Dis. 2003 Feb;62(2):127-32
pubmed: 12525381
Rheumatol Ther. 2020 Dec;7(4):867-882
pubmed: 32939675
Ann Rheum Dis. 2009 Jun;68(6):777-83
pubmed: 19297344
JAMA. 1999 Dec 1;282(21):2012-8
pubmed: 10591383
J Clin Endocrinol Metab. 2001 Mar;86(3):1154-9
pubmed: 11238501
Front Med (Lausanne). 2018 Mar 12;5:62
pubmed: 29594122
Joint Bone Spine. 2018 Jul;85(4):447-453
pubmed: 28754402
Ann Intern Med. 2015 Aug 18;163(4):245-53
pubmed: 26121190
J Am Coll Cardiol. 2006 Jul 18;48(2):396-401
pubmed: 16843192
Eur Heart J. 2012 Jan;33(2):213-20
pubmed: 21719451
Ann Rheum Dis. 2005 Jan;64(1):127-9
pubmed: 15051621